Chlamydia trachomatis in Iceland: Prevalence, Clinico-epidemiological Features and Comparison of Cobas 480 CT/NG and Aptima Combo 2 (CT/NG) for Diagnosis.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Arnardóttir, Eva Mjöll
Jóhannesdóttir, Elísabet Reykdal
MetadataShow full item record
CitationHilmarsdóttir I, Arnardóttir EM, Jóhannesdóttir ER, Golparian D, Unemo M. Chlamydia trachomatis in Iceland: Prevalence, Clinico-epidemiological Features and Comparison of Cobas 480 CT/NG and Aptima Combo 2 (CT/NG) for Diagnosis. Acta Derm Venereol. 2021 Feb 11;101(2):adv00393. doi: 10.2340/00015555-3762.
AbstractThe aims of this study were to assess the prevalence of, and risk factors for, Chlamydia trachomatis in attendees recruited prospectively from October 2018 to January 2019 at the only sexually transmitted infections clinic in Iceland (in Reykjavík), and to evaluate the cobas 4800 CT/NG Test and Aptima Combo 2 Assay for C. trachomatis detection in male urine and female vaginal swabs. Prevalence of C. trachomatis was 15.8% among 487 women and 13.6% among 491 men (no Neisseria gonorrhoeae positive patients were found). C. trachomatis detection was independently and positively associated with being tested for contact tracing, 18-24 years of age, and reporting ≥ 6 sexual partners within 12 months. Reporting sex with non-residents of Iceland was associated with a lower risk of C. trachomatis infection. Both assays had a high sensitivity in detection of C. trachomatis (Aptima Combo 2: 100%; cobas 4800 CT/NG: 95.1%) and high specificity (100% and 99.6%, respectively). The high local prevalence of C. trachomatis and increased acquisition risk following sex with residents are of public health concern. Keywords: Iceland; Neisseria gonorrhoeae; nucleic acid amplification; prevalence; risk factor; sexually transmitted disease; Chlamydia trachomatis.
DescriptionTo access publisher's full text version of this article click on the hyperlink below
- Performance of the Abbott RealTime CT/NG for detection of Chlamydia trachomatis and Neisseria gonorrhoeae.
- Authors: Gaydos CA, Cartwright CP, Colaninno P, Welsch J, Holden J, Ho SY, Webb EM, Anderson C, Bertuzis R, Zhang L, Miller T, Leckie G, Abravaya K, Robinson J
- Issue date: 2010 Sep
- Evaluation of the Performance of the Cobas CT/NG Test for Use on the Cobas 6800/8800 Systems for Detection of <i>Chlamydia trachomatis</i> and <i>Neisseria gonorrhoeae</i> in Male and Female Urogenital Samples.
- Authors: Van Der Pol B, Fife K, Taylor SN, Nye MB, Chavoustie SE, Eisenberg DL, Crane L, Hirsch G, Arcenas R, Marlowe EM
- Issue date: 2019 Apr
- Detection of Chlamydia trachomatis and Neisseria gonorrhoeae in urogenital and oral specimens using the cobas® 4800, APTIMA Combo 2® TMA, and ProbeTec™ ET SDA assays.
- Authors: Kumamoto Y, Matsumoto T, Fujisawa M, Arakawa S
- Issue date: 2012 Jun
- High-volume workflow and performance comparisons for Chlamydia trachomatis and Neisseria gonorrhoeae testing using automated molecular platforms.
- Authors: Frontzek A, Aretzweiler G, Winkens D, Duncan D, Marlowe EM
- Issue date: 2019 Sep 11
- Head-to-head comparison of second-generation nucleic acid amplification tests for detection of Chlamydia trachomatis and Neisseria gonorrhoeae on urine samples from female subjects and self-collected vaginal swabs.
- Authors: Chernesky M, Jang D, Gilchrist J, Hatchette T, Poirier A, Flandin JF, Smieja M, Ratnam S
- Issue date: 2014 Jul